| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | K9; CK-9; EPPK |
| Entrez GeneID | 3857 |
| WB Predicted band size | Calculated MW: 62 kDa; Observed MW: 62 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Recombinant protein of human Cytokeratin 9 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3-4篇关于 **Cytokeratin 9(CK9)抗体** 的参考文献及其简要摘要：
---
1. **《Mutations in the 1A domain of keratin 9 in patients with epidermolytic palmoplantar keratoderma》**
- **作者**: Rothnagel JA, et al.
- **摘要**: 研究报道了CK9基因(*KRT9*)突变与遗传性掌跖角化症(EPPK)的关联，通过抗体定位发现突变导致CK9在表皮基底层以上异常聚集，影响细胞骨架稳定性。
2. **《Immunohistochemical analysis of cytokeratin 9 expression in human hair follicles》**
- **作者**: Fujimoto T, et al.
- **摘要**: 利用CK9特异性抗体揭示其在毛囊内根鞘中的特异性表达，提示CK9在毛囊角质化及毛发结构维持中的关键作用。
3. **《Cytokeratin 9 as a marker for hyperproliferative keratinocytes in psoriasis》**
- **作者**: Leigh IM, et al.
- **摘要**: 通过抗体染色发现，银屑病皮损中CK9表达显著上调，表明其可作为表皮过度增殖的生物学标志物。
4. **《Characterization of a monoclonal antibody specific to human cytokeratin 9 and its diagnostic applications》**
- **作者**: Wesselmann U, et al.
- **摘要**: 研究开发了一种高特异性CK9单克隆抗体，验证其在皮肤病理诊断(如鳞状上皮病变鉴别)中的潜在应用价值。
---
以上文献涵盖了CK9的基因突变、生理功能、病理机制及抗体开发应用等领域。如需具体DOI或期刊信息，建议通过PubMed或Web of Science检索作者及标题获取全文。
Cytokeratin 9 (CK9) is a type I intermediate filament protein belonging to the cytokeratin family, which forms essential structural components of epithelial cell cytoskeletons. It is primarily expressed in the suprabasal layers of stratified epithelia, particularly in palmoplantar (palm and sole) epidermis. CK9 plays a critical role in maintaining mechanical integrity and stress resistance in high-friction regions. Its mutation is linked to epidermolytic palmoplantar keratoderma (EPPK), a hereditary skin disorder characterized by hyperkeratosis and blistering.
Antibodies targeting CK9 are valuable tools in research and diagnostics. They are widely used in immunohistochemistry (IHC) to identify CK9 expression patterns in tissues, aiding in the study of epithelial differentiation and skin pathology. In clinical settings, CK9 antibodies help distinguish specific epithelial tumors or hyperproliferative skin conditions, as CK9’s restricted expression makes it a selective marker for palmoplantar keratinocytes. Commercially available CK9 antibodies are typically monoclonal, generated using recombinant CK9 or peptide immunogens. Validation includes reactivity testing via Western blotting and IHC on human skin sections. Cross-reactivity with other cytokeratins (e.g., CK10) must be ruled out due to structural similarities. Recent studies also explore CK9's role in epithelial barrier function and wound healing, expanding its relevance in dermatological research.
×
